Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Bladder Cancer, June 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 241 articles:
HTML format


 

Single Articles

  1. BAIRD B, Bilgili A, Anderson A, Carames G, et al
    Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer.
    Int Braz J Urol. 2023;49:479-489.
    PubMed    
    Abstract available

  2. ELSAYED DH, Elfarargy OM, Elderey MS, Mandour D, et al
    Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Contemp Oncol (Pozn). 2023;27:1-9.
    PubMed    
    Abstract available

  3. YANG C, Li Q, Chen X, Zhang Z, et al
    Correction for: Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation.
    Aging (Albany NY). 2023;undefined.
    PubMed    


  4. RETZ M, Kirchhoff FP, von Amsberg G, De Santis M, et al
    [Sequential therapy of advanced bladder cancer after prior perioperative systemic treatment : Recommendations from the Interdisciplinary Bladder Carcinoma Working Group (IABC) of the DKG e. V.].
    Urologie. 2023 Jun 1. doi: 10.1007/s00120-023-02098.
    PubMed    
    Abstract available

  5. LIU Y, Hu B, Pei X, Li J, et al
    A non-G-Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer.
    Adv Healthc Mater. 2023 Jun 1:e2300791. doi: 10.1002/adhm.202300791.
    PubMed    
    Abstract available

  6. MACDONALD A, Mehrnoush V, Ismail A, Di Matteo L, et al
    History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer.
    Arch Ital Urol Androl. 2023 May 31:11380. doi: 10.4081/aiua.2023.11380.
    PubMed    
    Abstract available

  7. ZHANG L, Liu B, Deng QH, Li JX, et al
    Retraction Note: LncRNA BRE-AS1 acts as a tumor suppressor factor in bladder cancer via mediating STAT3.
    Eur Rev Med Pharmacol Sci. 2023;27:4326.
    PubMed    
    Abstract available

  8. VAN HOOGSTRATEN LMC, Man CCO, Witjes JA, Meijer RP, et al
    Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    World J Urol. 2023 May 31:1-9. doi: 10.1007/s00345-023-04443.
    PubMed    
    Abstract available

  9. YAN B, Li X, Peng M, Zuo Y, et al
    The YTHDC1/GLUT3/RNF183 axis forms a positive feedback loop that modulates glucose metabolism and bladder cancer progression.
    Exp Mol Med. 2023 Jun 1. doi: 10.1038/s12276-023-00997.
    PubMed    
    Abstract available

  10. CHAPPIDI MR, Escobar D, Meng MV, Washington SL 3rd, et al
    Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols.
    Urol Oncol. 2023 May 29:S1078-1439(23)00172.
    PubMed    
    Abstract available

  11. WANG D, Liu Y
    Comment on "The prognostic impact of tumor necrosis in non-muscle invasive bladder cancer".
    Rev Assoc Med Bras (1992). 2023;69:e20230295.
    PubMed    


  12. SIREGAR GP, Parwati I, Noegroho BS, Safridai F, et al
    The association between serum hypoxia inducible factor-1alpha level and urothelial bladder cancer: A preliminary study.
    Arch Ital Urol Androl. 2023 May 29:11292. doi: 10.4081/aiua.2023.11292.
    PubMed    
    Abstract available

  13. SOHNGEN C, Thomas DJ, Skowron MA, Bremmer F, et al
    CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
    FEBS J. 2023 May 31. doi: 10.1111/febs.16880.
    PubMed    
    Abstract available

  14. ZHANGHUANG C, Zhang Z, Wang J, Yao Z, et al
    Surveillance of prognostic risk factors in patients with SCCB using artificial intelligence: a retrospective study.
    Sci Rep. 2023;13:8727.
    PubMed    
    Abstract available

  15. ZENG N, Xu MY, Sun JX, Liu CQ, et al
    Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: a network meta-analysis.
    Front Oncol. 2023;13:1164932.
    PubMed    
    Abstract available

  16. DU Y, Miao W, Jiang X, Cao J, et al
    Corrigendum: The epithelial to mesenchymal transition related gene calumenin is an adverse prognostic factor of bladder cancer correlated with tumor microenvironment remodeling, gene mutation, and ferroptosis.
    Front Oncol. 2023;13:1185029.
    PubMed    
    Abstract available

  17. UEMATSU R, Teishima J, Sakata H, Mita Y, et al
    Peritoneal and pulmonary tuberculosis following intravesical administration of Bacillus Calmette-Guerin for bladder cancer.
    Int Cancer Conf J. 2023;12:221-225.
    PubMed    
    Abstract available

  18. KONO S, Hashimoto Y, Shirai Y, Kunihiro Y, et al
    A long-term survival case of bladder cancer with distant metastases: abscopal effect of brain metastases after stereotactic radiotherapy with immune checkpoint blockade therapy to lung metastases.
    Int Cancer Conf J. 2023;12:205-209.
    PubMed    
    Abstract available

  19. DOLNY M, Czajkowski M, Czajkowska K, Sokolowska-Wojdylo M, et al
    Penile metastasis secondary to urothelial bladder cancer.
    Urol Case Rep. 2023;49:102428.
    PubMed    
    Abstract available

  20. TORTORA D, Roberts ME, Kumar G, Kotapalli SS, et al
    A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer.
    iScience. 2023;26:106525.
    PubMed    
    Abstract available

  21. COSTA L, Alexandre T, Mansinho A, Sousa R, et al
    Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in Portugal.
    Front Public Health. 2023;11:1133959.
    PubMed    
    Abstract available

  22. ZHANG ZC, Zhao HF, Sun Z, Li Y, et al
    Tripartite motif-containing 9 promoted proliferation and migration of bladder cancer cells through CEACAM6-Smad2/3 axis.
    J Cell Commun Signal. 2023 May 30. doi: 10.1007/s12079-023-00766.
    PubMed    
    Abstract available

  23. LIU Y, Yu H, Zeng B, Gou X, et al
    miR-383-5p serves as a tumor suppressor in bladder cancer by suppressing PI3K/AKT signaling pathway.
    Cancer Biomark. 2023 May 18. doi: 10.3233/CBM-220379.
    PubMed    
    Abstract available

  24. ZHU PY, Wang L, Li KP, Yin S, et al
    Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and pooled analysis of comparative outcomes.
    World J Surg Oncol. 2023;21:163.
    PubMed    
    Abstract available

  25. MALALASEKERA A, Neththikumara N, Somasundaram P, Pathirana S, et al
    Clinical Exome Gene Panel Analysis of a Cohort of Urothelial Bladder Cancer Patients from Sri Lanka.
    Asian Pac J Cancer Prev. 2023;24:1533-1542.
    PubMed    
    Abstract available

  26. CHEN Y, Zhang Y, Wang X, Qiao S, et al
    Methylseleninic acid induces apoptosis of human bladder cancer cells through the ROS-mediated mitochondrial pathway.
    J Biochem Mol Toxicol. 2023 May 29:e23387. doi: 10.1002/jbt.23387.
    PubMed    
    Abstract available

  27. DOWNES MR, Hartmann A, Shen S, Tsuzuki T, et al
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance.
    Am J Surg Pathol. 2023 May 29. doi: 10.1097/PAS.0000000000002059.
    PubMed    
    Abstract available

  28. ZHANG N, Bian Q, Gao Y, Wang Q, et al
    The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?
    Technol Cancer Res Treat. 2023;22:15330338231175733.
    PubMed    
    Abstract available

  29. GALLUZZO A, Danti G, Bicci E, Mastrorosato M, et al
    The Role of Dual-Energy CT in the Study of Urinary Tract Tumors: Review of Recent Literature.
    Semin Ultrasound CT MR. 2023;44:136-144.
    PubMed    
    Abstract available

  30. SHI X, Dong A, Yang Y, Zheng G, et al
    Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
    J Cancer Res Clin Oncol. 2023 May 27. doi: 10.1007/s00432-023-04881.
    PubMed    
    Abstract available

  31. CLAPS F, Rossin G, van Rhijn BWG, Mir MC, et al
    The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer.
    Medicina (Kaunas). 2023;59:926.
    PubMed    
    Abstract available

  32. MOHANTY SK, Lobo A, Mishra SK, Cheng L, et al
    Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
    J Pers Med. 2023;13:756.
    PubMed    
    Abstract available

  33. EINERHAND SMH, Zuur LG, Wondergem MJ, Boellaard TN, et al
    The Implementation of FDG PET/CT for Staging Bladder Cancer: Changes in the Detection and Characteristics of Occult Nodal Metastases at Upfront Radical Cystectomy?
    J Clin Med. 2023;12:3367.
    PubMed    
    Abstract available

  34. SZALLASI A
    "ThermoTRP" Channel Expression in Cancers: Implications for Diagnosis and Prognosis (Practical Approach by a Pathologist).
    Int J Mol Sci. 2023;24:9098.
    PubMed    
    Abstract available

  35. WATANABE R, Miura N, Kurata M, Kitazawa R, et al
    Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
    Int J Mol Sci. 2023;24:8955.
    PubMed    
    Abstract available

  36. SMITH V, Lee D, Reardon M, Shabbir R, et al
    Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2023;24:8956.
    PubMed    
    Abstract available

  37. OKUNO Y, Hattori-Kato M, Tanaka H, Tonooka A, et al
    Relationship between the Reduced Expression of Zinc Finger Protein 668 in Bladder Cancer and Its Invasiveness.
    Int J Mol Sci. 2023;24:8668.
    PubMed    
    Abstract available

  38. WANG BR, Chang WS, Liao CH, Wang YC, et al
    Impacts of Mir146a Genotypes on Bladder Cancer Risk in Taiwan.
    Biomedicines. 2023;11:1396.
    PubMed    
    Abstract available

  39. SPIRITO L, Maturi R, Credendino SC, Manfredi C, et al
    Differential Expression of LncRNA in Bladder Cancer Development.
    Diagnostics (Basel). 2023;13:1745.
    PubMed    
    Abstract available

  40. STRAUSS J, Deville JL, Sznol M, Ravaud A, et al
    First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
    J Immunother Cancer. 2023;11:e005813.
    PubMed    
    Abstract available

  41. JIANG LJ, Guo SB, Huang ZY, Li XL, et al
    PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/beta-catenin signaling pathway.
    Pathol Res Pract. 2023;247:154536.
    PubMed    
    Abstract available

  42. YANG CH, Hsu CY, Lin YS, Tung MC, et al
    One-Step Robot-Assisted Complete Urinary Tract Extirpation in Man with End-Stage Renal Disease on Dialysis: The First Case Report.
    Curr Oncol. 2023;30:5093-5102.
    PubMed    
    Abstract available

  43. DAI S, Liu C, Jiang Z, Teng X, et al
    Three-port approach vs conventional laparoscopic radical cystectomy with orthotopic neobladder: a single-center retrospective study.
    World J Surg Oncol. 2023;21:160.
    PubMed    
    Abstract available

  44. SAVELEVA MS, Lobanov ME, Gusliakova OI, Plastun VO, et al
    Mucoadhesive Emulsion Microgels for Intravesical Drug Delivery: Preparation, Retention at Urothelium, and Biodistribution Study.
    ACS Appl Mater Interfaces. 2023;15:25354-25368.
    PubMed    
    Abstract available

  45. TANG Q, Li S, Huang G, Liu H, et al
    Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
    Int Immunopharmacol. 2023;119:110158.
    PubMed    
    Abstract available

  46. ANIS O, Yogev D, Dotan A, Tsur AM, et al
    Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review.
    Autoimmun Rev. 2023;22:103329.
    PubMed    
    Abstract available

  47. ZHONG B, Wang Y, Liao Y, Liang J, et al
    MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
    Apoptosis. 2023;28.
    PubMed    
    Abstract available

  48. BAHCECI D, Nguyen JK, Sangoi AR, Stohr BA, et al
    Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.
    Hum Pathol. 2023;136:56-62.
    PubMed    
    Abstract available

  49. GONZALEZ N, Rao N, Dean M, Lee D, et al
    Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors.
    Cancer Epidemiol Biomarkers Prev. 2023;32:840-847.
    PubMed    
    Abstract available

  50. SU R, Chen Z, Hong D, Jiang S, et al
    Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
    Cancer Med. 2023;12:10587-10596.
    PubMed    
    Abstract available

  51. MOON JH, Nikas IP, Moon KC, Kim B, et al
    Clinical application of the anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) immunocytochemistry in liquid-based urine cytology: A prospective, single institute study.
    Cancer Med. 2023;12:10363-10370.
    PubMed    
    Abstract available

  52. TURAL D, Arslan C, Selcukbiricik F, Olmez OF, et al
    Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice.
    Clin Genitourin Cancer. 2023;21:334-341.
    PubMed    
    Abstract available

  53. PATEL KN, Salunke A, Sharma M, Puj K, et al
    Development and Internal Validation of a Nomogram Predicting Overall Survival Based on Log ODDS of Positive Lymph-Nodes for Post Radical Cystectomy Patients in Muscle Invasive Carcinoma of Bladder.
    Clin Genitourin Cancer. 2023;21:e153-e165.
    PubMed    
    Abstract available

  54. GELLINGS P, Galeas-Pena M, Morici LA
    Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.
    Clin Exp Med. 2023;23:519-527.
    PubMed    
    Abstract available

  55. ZHENG P, Wu K, Gao Z, Li H, et al
    [Retracted] KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3.
    Int J Mol Med. 2023;52:62.
    PubMed    
    Abstract available

  56. VAN DER KWAST TH, Bubendorf L, Cheng L
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Progresses and Challenges.
    Am J Surg Pathol. 2023 Jun 8. doi: 10.1097/PAS.0000000000002066.
    PubMed    


  57. ZHOU H, Wang P, Qin X, Zhang X, et al
    Comparative transcriptomic analysis and mechanistic characterization revealed the use of formononetin for bladder cancer treatment.
    Food Funct. 2023 Jun 8. doi: 10.1039/d2fo03962.
    PubMed    
    Abstract available

  58. VOLZ Y, Trappmann R, Ebner B, Eismann L, et al
    Absence of detrusor muscle in TUR-BT specimen - can we predict who is at highest risk?
    BMC Urol. 2023;23:106.
    PubMed    
    Abstract available

  59. ERDIK A, Cimen HI, Kose O, Ates OF, et al
    Can pelvic diameter measurement have an effect on surgical outcomes in radical cystectomy?
    BMC Urol. 2023;23:105.
    PubMed    
    Abstract available

  60. LU J, Li X, Chen M, Yang P, et al
    Perivesical Fat Invasive Pattern as Prognostic Factor and Predictor of Response to Adjuvant Chemotherapy in T3 Stage Bladder Cancer.
    Clin Genitourin Cancer. 2023 May 7:S1558-7673(23)00105.
    PubMed    
    Abstract available

  61. PETRAUSCH U, Spahn M, Schneider M, Hayoz S, et al
    Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol
    BMJ Open. 2023;13:e067634.
    PubMed    
    Abstract available

  62. ZHANG W, Mao S, Shi D, Zhang J, et al
    Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1.
    Front Oncol. 2023;13:1208728.
    PubMed    
    Abstract available

  63. XU C, Zou W, Zhang L, Xu R, et al
    Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.
    Front Immunol. 2023;14:1162580.
    PubMed    
    Abstract available

  64. WU W, Chen L, Jia G, Tang Q, et al
    Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.
    Cancer Med. 2023 Jun 7. doi: 10.1002/cam4.6172.
    PubMed    
    Abstract available

  65. XU C, Chen A, Mao C, Cui B, et al
    Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:139-147.
    PubMed    
    Abstract available

  66. LINDNER AK, Lackner F, Tymoszuk P, Barth DA, et al
    Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Biol Sex Differ. 2023;14:38.
    PubMed    
    Abstract available

  67. WU R, Teng X, Song Q, Chen S, et al
    Single-cell RNA sequencing reveals sexual diversity in the human bladder and its prospective impacts on bladder cancer and urinary tract infection.
    BMC Med Genomics. 2023;16:122.
    PubMed    
    Abstract available

  68. ZHENG J, Miao F, Wang Z, Ma Y, et al
    Identification of MDM2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
    Life Sci. 2023 Jun 3:121832. doi: 10.1016/j.lfs.2023.121832.
    PubMed    
    Abstract available

  69. YANG CJ, Tan ZL, Yang JD, Hsu FT, et al
    Fluoxetine inactivates STAT3/NF-kappaB signaling and promotes sensitivity to cisplatin in bladder cancer.
    Biomed Pharmacother. 2023;164:114962.
    PubMed    
    Abstract available

  70. DONG Y, Xu C, Su G, Li Y, et al
    Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation.
    Front Immunol. 2023;14:1122570.
    PubMed    
    Abstract available

  71. HERRANZ R, Oto J, Hueso M, Plana E, et al
    Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.
    Front Immunol. 2023;14:1171065.
    PubMed    
    Abstract available

  72. DERGAMOUN H, El Gdaouni A, Taoufik A, Ziouziou I, et al
    Inflammatory myofibroblastic tumor of the urinary bladder: a case report.
    Pan Afr Med J. 2023;44:119.
    PubMed    
    Abstract available

  73. LIU X, Li X, Kuang Q, Luo H, et al
    Screening of immunotherapy-related genes in bladder cancer based on GEO datasets.
    Front Oncol. 2023;13:1176637.
    PubMed    
    Abstract available

  74. KAGAMI LP, Goncalves IL, da Silva AC, Silva AC, et al
    LaSOM 335, active against bladder cancer cells, interferes with Let-60 (hRas) and reduces CD73 expression/activity.
    Chem Biol Drug Des. 2023 Jun 5. doi: 10.1111/cbdd.14273.
    PubMed    
    Abstract available

  75. SODA T, Tashiro Y, Koike S, Ikeuchi R, et al
    Evaluation of incidence, predictive factors and treatment considerations for asymptomatic genitourinary granulomas after intravesical bacillus Calmette-Guerin therapy.
    Actas Urol Esp (Engl Ed). 2023;47:317-326.
    PubMed    
    Abstract available

  76. WANG S, Ge C
    High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid.
    J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04867.
    PubMed    
    Abstract available

  77. LICHTBROUN B, Srivastava A, Ghodoussipour S
    A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For High-grade T1 Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2023 Jun 1:S2405-4569(23)00121-9. doi: 10.1016/j.euf.2023.
    PubMed    
    Abstract available

  78. WU S, Hong G, Lin T
    Artificial intelligence-based model for lymph node metastases detection in bladder cancer - Authors' reply.
    Lancet Oncol. 2023;24:e234.
    PubMed    


  79. MAI Z, Zhou Y, Zhou Z, Yan W, et al
    Artificial intelligence-based model for lymph node metastases detection in bladder cancer.
    Lancet Oncol. 2023;24:e233.
    PubMed    


  80. ZOU K, Lu M, Peng Y, Tang X, et al
    Artifical intelligence-based model for lymph node metastases detection in bladder cancer.
    Lancet Oncol. 2023;24:e232.
    PubMed    


  81. WANG C, Liu T, Wang J, Cheng C, et al
    CircHIPK3 negatively regulates autophagy by blocking VCP binding to the Beclin 1 complex in bladder cancer.
    Discov Oncol. 2023;14:86.
    PubMed    
    Abstract available

  82. SUN YF, Chen L, Xia QJ, Wang TH, et al
    Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.
    J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04886.
    PubMed    
    Abstract available

  83. CHEN C, Chao Y, Zhang C, Hu W, et al
    TROP2 translation mediated by dual m(6)A/m(7)G RNA modifications promotes bladder cancer development.
    Cancer Lett. 2023 May 31:216246. doi: 10.1016/j.canlet.2023.216246.
    PubMed    
    Abstract available

  84. HUANG EY, Tai MC, Chung HJ, Chang YH, et al
    Effects of different combinations of radical nephroureterectomy and bladder cuff excision procedures for upper tract urothelial carcinoma on bladder recurrence.
    Int Braz J Urol. 2023;49:469-478.
    PubMed    
    Abstract available

  85. KRANZ J, Hoffmann M, Alexa R, Kuppe C, et al
    [Urothelial carcinoma of the upper urinary tract].
    Urologie. 2023;62:640-650.
    PubMed    
    Abstract available

  86. GAVRILOVSKA-BRZANOV A, Seidi S, Stavridis S, Ivanovski O, et al
    Obturator Nerve Block for Transurethral Resection of Bladder Tumors.
    Med Arch. 2023;77:118-122.
    PubMed    
    Abstract available

  87. KARTTUNEN E, Oldenburg J, Thoresen S, Ullen A, et al
    Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic count
    Scand J Urol. 2023;58:20.
    PubMed    


  88. CHEN X, Cheng Y, Tian X, Li J, et al
    Urinary microbiota and metabolic signatures associated with inorganic arsenic-induced early bladder lesions.
    Ecotoxicol Environ Saf. 2023;259:115010.
    PubMed    
    Abstract available

  89. SONG Y, Xu T
    Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder.
    World J Urol. 2023;41:1697-1698.
    PubMed    


  90. MAGOON R, Jose J, Suresh V
    Assessing postradical cystectomy outcomes in the enhanced recovery era: "enhancing" the corresponding research outlook.
    Urol Oncol. 2023;41:292.
    PubMed    


  91. VAHLENSIECK W
    [Interstitial cystitis/bladder pain syndrome (IC/BPS)].
    Urologie. 2023;62:582-589.
    PubMed    
    Abstract available

  92. KUMAR R, Matulewicz R, Mari A, Moschini M, et al
    Impact of smoking on urologic cancers: a snapshot of current evidence.
    World J Urol. 2023;41:1473-1479.
    PubMed    
    Abstract available

  93. BRUCH PG, Plage H, Hofbauer S, Kornienko K, et al
    Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
    Exp Mol Pathol. 2023;131:104860.
    PubMed    
    Abstract available

  94. DIAMANTOPOULOS LN, Makrakis D, Korentzelos D, Alevizakos M, et al
    Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma.
    Urol Oncol. 2023;41:296.
    PubMed    
    Abstract available

  95. ZHU Y, Geng Z, Lin Q
    Primary intestinal adenocarcinoma after orthotopic ileal neobladder.
    Asian J Surg. 2023;46:2321-2322.
    PubMed    


  96. HARVEY SE, VandenBussche CJ
    Nuclear membrane irregularity in high-grade urothelial carcinoma cells can be measured by using circularity and solidity as morphometric shape definitions in digital image analysis of urinary tract cytology specimens.
    Cancer Cytopathol. 2023;131:351-359.
    PubMed    
    Abstract available

  97. CHIN CP, Smith WH, Cesaretti J, Terk M, et al
    Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.
    Urol Oncol. 2023;41:296.
    PubMed    
    Abstract available

  98. BAI SJ, Chen XB, Zeng TB
    Treatment progress of cystitis glandularis.
    Asian J Surg. 2023;46:2444.
    PubMed    


  99. SHEN H, Lv C
    Multiple primary trans-systemic triple carcinoma: A rare case report.
    Asian J Surg. 2023;46:2466-2467.
    PubMed    


  100. BAIRD BA, Taylor T, Brennan E, Borkar S, et al
    Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida.
    Urol Oncol. 2023;41:294.
    PubMed    
    Abstract available

  101. FONTANET S, Gallioli A, Baboudjian M, Huguet J, et al
    Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary tract carcinoma in situ: A single institution series and systematic review.
    Urol Oncol. 2023;41:274-283.
    PubMed    
    Abstract available

  102. DUDINEC JV, Ortiz-Melo DI, Lipkin ME, Abern MR, et al
    Advanced chronic kidney disease; A comparison between nephroureterectomy and nephron-sparing surgery for upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:295.
    PubMed    
    Abstract available

  103. TAI P, Wang Z, Chen X, Chen A, et al
    Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Cancer Med. 2023;12:11941-11959.
    PubMed    
    Abstract available

  104. VELEZ TORRES JM, Gonzalez ML, Duarte EM, Zein-Sabatto B, et al
    Urine Cytology Findings in Cases of Pseudocarcinomatous Urothelial Hyperplasia of the Bladder Often Represent a Diagnostic Challenge.
    Arch Pathol Lab Med. 2023;147:716-721.
    PubMed    
    Abstract available

  105. YOO Y, Kim JM, Choi E, Park HS, et al
    The Effect of Complete Prostate Examination of Radical Cystoprostatectomy Specimen on the Final Stage of Urothelial Carcinoma of the Urinary Bladder and the Detection of Prostate Cancer.
    Arch Pathol Lab Med. 2023;147:665-675.
    PubMed    
    Abstract available

  106. SHI T, Yuan Z, He Y, Zhang D, et al
    Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer.
    Cell Oncol (Dordr). 2023 Jun 16. doi: 10.1007/s13402-023-00823.
    PubMed    
    Abstract available

  107. LIU X, Wu Y, Zhou Z, Huang M, et al
    [Corrigendum] Celecoxib inhibits the epithelial‑to‑mesenchymal transition in bladder cancer via the miRNA‑145/TGFBR2/Smad3 axis.
    Int J Mol Med. 2023;52:64.
    PubMed    
    Abstract available

  108. CHEN H, Yang W, Li Y, Ma L, et al
    Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.
    Front Immunol. 2023;14:1198878.
    PubMed    
    Abstract available

  109. XUE Y, Zhao G, Pu X, Jiao F, et al
    Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA.
    Front Oncol. 2023;13:1196802.
    PubMed    
    Abstract available

  110. BOOT IWA, Wesselius A, Yu EYW, White E, et al
    Dietary vitamin D intake and the bladder cancer risk: A pooled analysis of prospective cohort studies.
    Clin Nutr. 2023 May 22:S0261-5614(23)00152-8. doi: 10.1016/j.clnu.2023.
    PubMed    
    Abstract available

  111. YANG X, Zhang S, He J, Zhao L, et al
    Brazilin inhibits bladder cancer by promoting cell necroptosis.
    Clin Exp Pharmacol Physiol. 2023 Jun 15. doi: 10.1111/1440-1681.13800.
    PubMed    
    Abstract available

  112. GALLAGHER K, Bhatt N, Clement K, Zimmermann E, et al
    Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study W
    JMIR Res Protoc. 2023;12:e42254.
    PubMed    
    Abstract available

  113. LIU S, Liu Z, Shang A, Xun J, et al
    CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis.
    Sci Rep. 2023;13:9657.
    PubMed    
    Abstract available

  114. STEELE TM, Tsamouri MM, Siddiqui S, Lucchesi CA, et al
    Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer.
    Sci Rep. 2023;13:9617.
    PubMed    
    Abstract available

  115. STONE BV, Labban M, Filipas DK, Beatrici E, et al
    The Risk of Catastrophic Healthcare Expenditures Among Prostate and Bladder Cancer Survivors in the United States.
    Clin Genitourin Cancer. 2023 May 27:S1558-7673(23)00135.
    PubMed    
    Abstract available

  116. LU XS, Huang ML, Chen LB, Liu SC, et al
    SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer.
    Genomics. 2023 Jun 12:110667. doi: 10.1016/j.ygeno.2023.110667.
    PubMed    
    Abstract available

  117. JIANG C, Perimbeti S, Deng L, Xing J, et al
    Medicaid Expansion and Racial Disparity in Timely Multidisciplinary Treatment in Muscle Invasive Bladder Cancer.
    J Natl Cancer Inst. 2023 Jun 14:djad112. doi: 10.1093.
    PubMed    
    Abstract available

  118. WANG L, Qi F, Bi L, Yan J, et al
    Targeted hollow pollen silica nanoparticles for enhanced intravesical therapy of bladder cancer.
    Biomater Sci. 2023 Jun 14. doi: 10.1039/d3bm00631.
    PubMed    
    Abstract available

  119. DALJIT T, Melgandi W, Ansari FA, Rathi AK, et al
    Cutaneous metastasis in bladder cancer.
    J Cancer Res Ther. 2023;19:501-504.
    PubMed    
    Abstract available

  120. ALAM MN, Agrawal S, Rastogi N, Saxena R, et al
    Chemotherapy or chemotherapy followed by consolidation chemoradiation in postoperative (simple cholecystectomy) gall bladder cancer with residual disease, unsuitable for revision surgery? Risk stratification and outcomes.
    J Cancer Res Ther. 2023;19:259-264.
    PubMed    
    Abstract available

  121. WU C, Duan L, Li H, Liu X, et al
    PD1(hi) CD200(hi) CD4(+) exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial-mesenchymal transition in bladder cancer.
    Clin Transl Med. 2023;13:e1303.
    PubMed    
    Abstract available

  122. AL-HUMAIRI RMA, Hashim Mohammad T, Thanoon Ahmed S, Ad'hiah AH, et al
    Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guerin and Mitomycin C in Superficial Bladder Cancer.
    Arch Razi Inst. 2023;78:353-360.
    PubMed    
    Abstract available

  123. NAMIKI S, Ueda S, Takeuchi Y, Kawase M, et al
    [A Case of Refractory Lymphatic Leakage after Robot-Assisted Radical Cystectomy].
    Hinyokika Kiyo. 2023;69:137-142.
    PubMed    
    Abstract available

  124. WANG Y, Song Y, Qin C, Zhang C, et al
    Effect of regional versus general anesthesia on recurrence of non-muscle invasive bladder cancer: a systematic review and meta-analysis of eight retrospective cohort studies.
    BMC Anesthesiol. 2023;23:201.
    PubMed    
    Abstract available

  125. ROUPRET M, Burger M, Stenzl A
    Letter to the Editor on the systematic review "Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer".
    World J Urol. 2023 Jun 13. doi: 10.1007/s00345-023-04435.
    PubMed    


  126. KIM JY, Yoon JH, Yoo KB, Lee WR, et al
    Disparity of Bladder Cancer Incidence among Male Workers across Industries: A Population-based Cohort Study from South Korea.
    J Occup Environ Med. 2023 Jun 12. doi: 10.1097/JOM.0000000000002907.
    PubMed    
    Abstract available

  127. WANG H, Ma X, Li S, Su J, et al
    KIF20A as a potential biomarker of renal and bladder cancers based on bioinformatics and experimental verification.
    Aging (Albany NY). 2023;15.
    PubMed    
    Abstract available

  128. CHEN Y, Huang M, Lu J, Zhang Q, et al
    Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer.
    Environ Toxicol. 2023 Jun 13. doi: 10.1002/tox.23860.
    PubMed    
    Abstract available

  129. KUKREJA JB
    Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.
    Eur Urol Focus. 2023 Jun 10:S2405-4569(23)00115.
    PubMed    
    Abstract available

  130. CHEN Y, Yin L, Hao M, Xu W, et al
    Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells.
    Acta Pharm. 2023;73:211-225.
    PubMed    
    Abstract available

  131. LIU B, Dan W, Wei Y, Zhang Y, et al
    beta-asarone inhibits the migration, invasion, and EMT of bladder cancer through activating ER stress.
    Cancer Med. 2023 Jun 12. doi: 10.1002/cam4.6059.
    PubMed    
    Abstract available

  132. LIU YS, Thaliffdeen R, Han S, Park C, et al
    Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review.
    Expert Rev Pharmacoecon Outcomes Res. 2023.
    PubMed    
    Abstract available

  133. HONG KU, Hein DW
    N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer.
    Pharmacogenet Genomics. 2023 May 29. doi: 10.1097/FPC.0000000000000500.
    PubMed    
    Abstract available

  134. FAN X, He W, Huang J
    Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives.
    Transl Androl Urol. 2023;12:802-808.
    PubMed    
    Abstract available

  135. HAO L, Fang J, Xu R, Liu S, et al
    Significance of the FGFR3 mutation in Chinese patients with bladder cancer.
    Transl Androl Urol. 2023;12:761-769.
    PubMed    
    Abstract available

  136. HU W, Zhang Y, Ning J, Li M, et al
    Corrigendum to "Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages" [Heliyon 9(3) (March 2023) e14272].
    Heliyon. 2023;9:e15303.
    PubMed    
    Abstract available

  137. NASSIR A, Saada H, Bakry S, Al-Zahrani S, et al
    Assessment of the knowledge and awareness of urinary bladder cancer among the general population in Western Saudi Arabia.
    Urol Ann. 2023;15:220-225.
    PubMed    
    Abstract available

  138. ALBAKRI M, Abu-Hijlih R, Salah S, Al-Ibraheem A, et al
    Bladder cancer in young adults: Disease and treatment characteristics of patients treated at a tertiary cancer center.
    Urol Ann. 2023;15:207-210.
    PubMed    
    Abstract available

  139. VILLOLDO GM, Pombo MT, Aris M, Chemi J, et al
    A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guerin in patients with non-muscle invasive bladder carcinoma: A retrospective study.
    Oncol Res. 2023;31:207-220.
    PubMed    
    Abstract available

  140. ERIKSSON P, Berg J, Bernardo C, Bobjer J, et al
    Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection.
    Eur Urol Open Sci. 2023;53:78-82.
    PubMed    
    Abstract available

  141. YIN J, Cai G, Wang H, Chen W, et al
    SIRT4 is an independent prognostic factor in bladder cancer and inhibits bladder cancer growth by suppressing autophagy.
    Cell Div. 2023;18:9.
    PubMed    
    Abstract available

  142. XU PH, Chen S, Wang Y, Jin S, et al
    FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
    Comput Biol Med. 2023;162:106976.
    PubMed    
    Abstract available

  143. XIA Z, Wang Q, Lu P
    LncRNA LINC00885 promotes bladder cancer progression by targeting the miR-98-5p/PBX3 axis.
    Cell Mol Biol (Noisy-le-grand). 2023;69:163-168.
    PubMed    
    Abstract available

  144. KHOURY R, Saleh K, Khalife N, Saleh M, et al
    Mechanisms of Resistance to Antibody-Drug Conjugates.
    Int J Mol Sci. 2023;24:9674.
    PubMed    
    Abstract available

  145. PAPASAVVA M, Amvrosiou S, Pilala KM, Soureas K, et al
    Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform.
    Int J Mol Sci. 2023;24:9258.
    PubMed    
    Abstract available

  146. MEHUS AA, Jones M, Trahan M, Kinnunen K, et al
    Pevonedistat Inhibits SOX2 Expression and Sphere Formation but Also Drives the Induction of Terminal Differentiation Markers and Apoptosis within Arsenite-Transformed Urothelial Cells.
    Int J Mol Sci. 2023;24:9149.
    PubMed    
    Abstract available

  147. ZHENG Q, Jian J, Wang J, Wang K, et al
    Predicting Lymph Node Metastasis Status from Primary Muscle-Invasive Bladder Cancer Histology Slides Using Deep Learning: A Retrospective Multicenter Study.
    Cancers (Basel). 2023;15:3000.
    PubMed    
    Abstract available

  148. BACCHIANI M, Salamone V, Massaro E, Sandulli A, et al
    Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.
    Cancers (Basel). 2023;15:2951.
    PubMed    
    Abstract available

  149. SU YL, Xiao LY, Huang SY, Wu CC, et al
    Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process.
    Cells. 2023;12:1471.
    PubMed    
    Abstract available

  150. NOEL OD, Stewart E, Cress R, Dall'Era MA, et al
    Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
    Urol Oncol. 2023 Jun 8:S1078-1439(23)00194-1. doi: 10.1016/j.urolonc.2023.
    PubMed    
    Abstract available

  151. ALI MY, Aboelsaad AY, Abdel Gawad AM, Abouelgreed TA, et al
    HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones.
    Arch Ital Urol Androl. 2023;95:11313.
    PubMed    
    Abstract available

  152. GRIZZI F, Chiriva-Internati M, Miranda E, Zaharie R, et al
    Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct.
    Pathol Res Pract. 2023;247:154546.
    PubMed    
    Abstract available

  153. CISTERNINO A, Capone L, Rosati A, Latiano C, et al
    New concept in urologic surgery: The total extended genital sparing radical cystectomy in women.
    Arch Ital Urol Androl. 2023;95:11058.
    PubMed    
    Abstract available

  154. NAGAHISA C, Unagami K, Banno T, Oki R, et al
    Kidney Transplantation After Multiple Urinary Tract Conversion with an Ileal Conduit: A Case Report.
    Transplant Proc. 2023 May 14:S0041-1345(23)00252.
    PubMed    
    Abstract available

  155. HANZE J, Schulte-Herbruggen J, Hofmann R, Hegele A, et al
    Modulation of immune checkpoint regulators in interferon gamma induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics.
    Genes Immun. 2023;24:149-153.
    PubMed    
    Abstract available

  156. DELL'OGLIO P, Tappero S, Panunzio A, Antonelli A, et al
    Age represents the main driver of surgical decision making in patients candidate to radical cystectomy.
    J Surg Oncol. 2023;128:142-154.
    PubMed    
    Abstract available

  157. AMIR M, Javed S
    Elucidation of binding dynamics of tyrosine kinase inhibitor tepotinib, to human serum albumin, using spectroscopic and computational approach.
    Int J Biol Macromol. 2023;241:124656.
    PubMed    
    Abstract available

  158. SPARWASSER P, Frey L, Fischer ND, Thomas A, et al
    First Comparison of Retroperitoneal Versus Transperitoneal Robot-Assisted Nephroureterectomy with Bladder Cuff: A Single Center Study.
    Ann Surg Oncol. 2023;30:4531-4539.
    PubMed    
    Abstract available

  159. MATSUKAWA A, Kimura S, Koike Y, Ajisaka S, et al
    Feasibility of Novel Technique of Flexible Cystoscopic En Bloc Snare Resection of Bladder Tumor: f-ESRBT.
    J Endourol. 2023;37:713-717.
    PubMed    
    Abstract available

  160. SAKUMO K, Morihashi K, Nakamura A, Nukaya T, et al
    The usefulness of nuclear area in the diagnosis of high-grade urothelial carcinoma cells in voided urine cytology.
    Cytopathology. 2023;34:295-301.
    PubMed    
    Abstract available

  161. CHEN M, Yao K, Cao M, Liu H, et al
    HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
    Cancer Immunol Immunother. 2023;72:2309-2318.
    PubMed    
    Abstract available

  162. NIELSEN TJ, Varga MG, Cronister CT, Ring BZ, et al
    The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
    Cancer Immunol Immunother. 2023;72:2075-2086.
    PubMed    
    Abstract available

  163. YAMADA S, Miyata H, Isono M, Hori K, et al
    Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
    Cancer Immunol Immunother. 2023;72:2057-2065.
    PubMed    
    Abstract available

  164. CHOUDHURY S, Kamble V, Jana D, Pal DK, et al
    Thulium laser enucleation of bladder tumour (Thulebt): Changing paradigm in the management of nonmuscle invasive urinary bladder carcinoma.
    Urologia. 2023;90:266-271.
    PubMed    
    Abstract available

  165. SAMI MM, Sherief MH, El-Abaseri TB, El-Sakka AI, et al
    Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance.
    Urologia. 2023;90:248-260.
    PubMed    
    Abstract available

  166. FISCHER AH, Wong JY, Baris D, Koutros S, et al
    Urine pH and Risk of Bladder Cancer in Northern New England.
    Cancer Epidemiol Biomarkers Prev. 2023 Jun 23:EPI-22-0801.
    PubMed    
    Abstract available

  167. DENG Z, Tang N, Xiong W, Lei X, et al
    Inflammation-related research within the field of bladder cancer: a bibliometric analysis.
    Front Oncol. 2023;13:1126897.
    PubMed    
    Abstract available

  168. WU Y, Deng Y, Dai Z, Ma Y, et al
    Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019.
    Cancer Med. 2023 Jun 23. doi: 10.1002/cam4.6219.
    PubMed    
    Abstract available

  169. ISALI I, Khooblall P, Helstrom E, Bukavina L, et al
    Targeting bladder cancer: A sex sensitive perspective in mutations and outcomes.
    Urol Oncol. 2023 Jun 20:S1078-1439(23)00166.
    PubMed    
    Abstract available

  170. DIEFENBACH MA, Marziliano A, Siembida EJ, Mistretta T, et al
    Cancer Resource and Information Support (CRIS) for Bladder Cancer Survivors and Their Caregivers: Development and Usability Testing Study.
    JMIR Form Res. 2023;7:e41876.
    PubMed    
    Abstract available

  171. AYDH A, Sari Motlagh R, Alamri A, Yanagisawa T, et al
    Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes.
    World J Urol. 2023 Jun 22. doi: 10.1007/s00345-023-04478.
    PubMed    
    Abstract available

  172. HE L, Wang X, Chen P, Du C, et al
    Knockdown of ZNF280A inhibits cell proliferation and promotes cell apoptosis of bladder cancer.
    Histol Histopathol. 2023 Jun 13:18640. doi: 10.14670.
    PubMed    
    Abstract available

  173. ZHI Y, Cai C, Xu T, Sun F, et al
    Silencing of FGF6 hampers aerobic glycolysis and angiogenesis in bladder cancer by regulating PI3K/Akt and MAPK signaling pathways.
    J Biochem Mol Toxicol. 2023 Jun 22:e23399. doi: 10.1002/jbt.23399.
    PubMed    
    Abstract available

  174. GEDERAAS OA, Sharma A, Mbarak S, Sporsheim B, et al
    Proteomic analysis reveals mechanisms underlying increased efficacy of bleomycin by photochemical internalization in bladder cancer cells.
    Mol Omics. 2023 Jun 22. doi: 10.1039/d2mo00337.
    PubMed    
    Abstract available

  175. LEE D, Lee W, Kim HP, Kim M, et al
    Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of Urine DNA.
    Cancers (Basel). 2023;15:2868.
    PubMed    
    Abstract available

  176. TICHANEK F, Forsti A, Hemminki A, Hemminki O, et al
    Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century.
    Cancers (Basel). 2023;15:2782.
    PubMed    
    Abstract available

  177. YOU C, Li Q, Yang Y, Qing L, et al
    Extraperitoneal Versus Intraperitoneal Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13744.
    PubMed    
    Abstract available

  178. BUNDELL S, Petric Howe N
    Why bladder cancer cells that shed their Y chromosome become more aggressive.
    Nature. 2023 Jun 21. doi: 10.1038/d41586-023-02069.
    PubMed    


  179. MEI Y, Wu Y, Ma L, Zhang H, et al
    Retraction Note: Overexpression of ROCK1 promotes cancer cell proliferation and is associated with poor prognosis in human urothelial bladder cancer.
    Mamm Genome. 2023 Jun 21. doi: 10.1007/s00335-023-10002.
    PubMed    


  180. MARK JR, Gomella LG, Lallas CD, Smentkowski KE, et al
    Enhancing bladder cancer care through the multidisciplinary clinic approach.
    Can J Urol. 2023;30:11526-11531.
    PubMed    
    Abstract available

  181. GHALI F, Vakar-Lopez F, Roudier MP, Garcia J, et al
    Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
    Clin Genitourin Cancer. 2023 May 25:S1558-7673(23)00132.
    PubMed    
    Abstract available

  182. CASTRO-ALONSO FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, et al
    Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
    Oncology (Williston Park). 2023;37:256-261.
    PubMed    
    Abstract available

  183. HANNA K
    Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
    Oncology (Williston Park). 2023;37:260-261.
    PubMed    


  184. YOU C, Dong Z
    ASO Author Reflections: A Safe and Feasible Procedure for Bladder Cancer-Extraperitoneal Radical Cystectomy.
    Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13789.
    PubMed    


  185. CHOI J, Jung TY, Kim JH, Maeng S, et al
    Efficacy of recombinant Bacillus Calmette-Guerin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model.
    Investig Clin Urol. 2023;64:296-305.
    PubMed    
    Abstract available

  186. WANG S, Yuan X, Shen Z, Zhao J, et al
    Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review.
    Investig Clin Urol. 2023;64:229-241.
    PubMed    
    Abstract available

  187. KIM KH, Lee HW, Ha HK, Seo HK, et al
    Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
    Investig Clin Urol. 2023;64:202-218.
    PubMed    
    Abstract available

  188. HU M, Pan D, Wei Y, Ye L, et al
    Atypical Recurrent Renal Cell Carcinoma of the Ipsilateral Ureter Showing Typical Symptoms of Upper Urinary Tract Urothelial Carcinoma: A Case Report and Literature Review.
    Arch Esp Urol. 2023;76:238-244.
    PubMed    
    Abstract available

  189. ZHOU Y, Yang H, Liang Z
    Efficiency and Safety of Laparoscopic Radical Cystectomy for Muscle-Invasive Bladder Cancer, and Postoperative Recurrence.
    Arch Esp Urol. 2023;76:196-202.
    PubMed    
    Abstract available

  190. LU X, Chen L, Liu S, Cao Y, et al
    m(6)A-mediated upregulation of lncRNA RMRP boosts the progression of bladder cancer via epigenetically suppressing SCARA5.
    Epigenomics. 2023 Jun 20. doi: 10.2217/epi-2023-0062.
    PubMed    
    Abstract available

  191. VERGHOTE F, Van Praet C, De Maeseneer D, Berquin C, et al
    Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium.
    Cancer Manag Res. 2023;15:511-521.
    PubMed    
    Abstract available

  192. LU Z, Lu Z, Lai Y, Zhou H, et al
    A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour microenvironment influencer.
    IET Syst Biol. 2023 Jun 19. doi: 10.1049/syb2.12067.
    PubMed    
    Abstract available

  193. WEI F, Li T, Li J, Zhang Y, et al
    Prognostic and Immunological Role of Asporin across Cancers and Exploration in Bladder Cancer.
    Gene. 2023 Jun 17:147573. doi: 10.1016/j.gene.2023.147573.
    PubMed    
    Abstract available

  194. LA MAESTRA S, Benvenuti M, D'Agostini F, Micale RT, et al
    Comet-FISH analysis of urothelial cells. A screening opportunity for bladder cancer?
    Expert Rev Mol Diagn. 2023 Jun 21:1-11. doi: 10.1080/14737159.2023.2227381.
    PubMed    
    Abstract available

  195. GRABE-HEYNE K, Henne C, Mariappan P, Geiges G, et al
    Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.
    Front Oncol. 2023;13:1170124.
    PubMed    
    Abstract available

  196. RADOSAVLJEVIC V, Milic N
    Bladder cancer screening: The new selection and prediction model.
    Open Med (Wars). 2023;18:20230723.
    PubMed    
    Abstract available

  197. MUKHERJEE D, Romano E, Walshaw R, Zeef LAH, et al
    Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
    Oncoimmunology. 2023;12:2223094.
    PubMed    
    Abstract available

  198. CRUPI E, de Padua TC, Marandino L, Raggi D, et al
    Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol Oncol. 2023 Jun 15:S2588-9311(23)00111.
    PubMed    
    Abstract available

  199. OH TJ, Lee JY, Seo Y, Woo MA, et al
    Evaluation of Sensitive Urine DNA-based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria.
    J Mol Diagn. 2023 Jun 15:S1525-1578(23)00131.
    PubMed    
    Abstract available

  200. VANNESTE M, van der Heij B, Christiaansen CE, Berendsen CL, et al
    Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
    World J Urol. 2023 Jun 17. doi: 10.1007/s00345-023-04469.
    PubMed    
    Abstract available

  201. ERYURUK U, Tasdemir MN, Aslan S
    Comparison of the diagnostic performance of biparametric and multiparametric MRI in detecting muscle invasion of bladder cancer located at the ureteral orifice.
    Abdom Radiol (NY). 2023 Jun 16. doi: 10.1007/s00261-023-03979.
    PubMed    
    Abstract available

  202. NIZIOL J, Ossolinski K, Plaza-Altamer A, Kolodziej A, et al
    Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
    Sci Rep. 2023;13:9802.
    PubMed    
    Abstract available

  203. TAN WS, Hall E, Kamat AM, Kelly JD, et al
    Clinical trial design for non-muscle-invasive bladder cancer.
    Nat Rev Urol. 2023 Jun 16. doi: 10.1038/s41585-023-00789.
    PubMed    


  204. YANG L, Huang W, Bai X, Wang H, et al
    Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling.
    Cell Death Dis. 2023;14:363.
    PubMed    
    Abstract available

  205. SINGH P, Rotte A, Golsorkhi AA, Girish S, et al
    Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective.
    Expert Rev Clin Pharmacol. 2023;16:533-548.
    PubMed    
    Abstract available

  206. HUGAR LA, Geiss C, Chavez MN, Gore LR, et al
    Exploring knowledge, perspectives, and misperceptions of palliative care: A mixed methods analysis.
    Urol Oncol. 2023;41:327.
    PubMed    
    Abstract available

  207. KHORSANDI N, Ding CC, VandenBussche CJ, Verduzco CS, et al
    Urine cytology in patients with gender confirmation surgery and hormone therapy: evaluation of urine cytology performance in an underserved patient population.
    J Am Soc Cytopathol. 2023;12:267-274.
    PubMed    
    Abstract available

  208. ZHANG C, Wang M, Ying Y, Meng F, et al
    Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and invasion while promoting apoptosis of urothelial bladder carcinoma cells.
    Cancer Med. 2023;12:12581-12592.
    PubMed    
    Abstract available

  209. COOK EE, Harrison BT, Hirsch MS
    TRPS1 expression is sensitive and specific for primary extramammary Paget disease.
    Histopathology. 2023;83:104-108.
    PubMed    
    Abstract available

  210. HENSLEY PJ, Seiler R, Herr H, Mouw KW, et al
    Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
    Urol Oncol. 2023;41:307-312.
    PubMed    
    Abstract available

  211. FERREIRA GM, Lima APB, Pereira GR, Silva GND, et al
    Synthesis, characterization and antiproliferative effects of naphtho [2,3-b] thiophen-4,9-quinone on bladder tumor cells.
    Nat Prod Res. 2023;37:2285-2292.
    PubMed    
    Abstract available

  212. CHI Z, Balani J, Gopal P, Hammer S, et al
    GATA3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma.
    J Clin Pathol. 2023;76:474-479.
    PubMed    
    Abstract available

  213. TAN WS, Grajales V, Bree K, Li R, et al
    BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
    BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
    PubMed    


  214. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
    Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
    BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
    PubMed    
    Abstract available


  215. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    PubMed    


  216. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
    Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
    BJU Int. 2023;132:84-91.
    PubMed    
    Abstract available

  217. YAMAMOTO S, Kato M, Takeyama Y, Azuma Y, et al
    Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.
    Br J Cancer. 2023;128:2197-2205.
    PubMed    
    Abstract available

  218. JANG HJ, Hostetter G, Macfarlane AW, Madaj Z, et al
    A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2023;29:2052-2065.
    PubMed    
    Abstract available

  219. MELLEMA JJ, van Rhijn BWG, van der Heijden MS
    Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jun 3. doi: 10.1097/MOU.0000000000001107.
    PubMed    
    Abstract available

  220. YANAGISAWA T, Kawada T, von Deimling M, Laukhtina E, et al
    Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023.
    Curr Opin Urol. 2023;33:258-268.
    PubMed    
    Abstract available

  221. MAKAROFF LE, Filicevas A, Boldon S, Hensley P, et al
    Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries.
    Eur Urol. 2023 May 24:S0302-2838(23)02801-4. doi: 10.1016/j.eururo.2023.
    PubMed    


  222. LAUKHTINA E, Shariat SF
    Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    Eur Urol. 2023 Jun 1:S0302-2838(23)02873-7. doi: 10.1016/j.eururo.2023.
    PubMed    


  223. O'CALLAGHAN M
    Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial.
    Eur Urol. 2023 Jun 9:S0302-2838(23)02871-3. doi: 10.1016/j.eururo.2023.
    PubMed    


  224. GRIVAS P, Park SH, Voog E, Caserta C, et al
    Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Eur Urol. 2023;84:95-108.
    PubMed    
    Abstract available

  225. ROUPRET M, Seisen T, Birtle AJ, Capoun O, et al
    European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
    Eur Urol. 2023;84:49-64.
    PubMed    
    Abstract available

  226. SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
    Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
    Eur Urol. 2023;84:117-126.
    PubMed    
    Abstract available

  227. LI Z, Jiang Y, Liu J, Fu H, et al
    Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway.
    Int J Oncol. 2023;63:84.
    PubMed    
    Abstract available

  228. SLUSARCZYK A, Zapala P, Olszewska-Slusarczyk Z, Radziszewski P, et al
    The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study.
    Int Urol Nephrol. 2023 Jun 6. doi: 10.1007/s11255-023-03655.
    PubMed    
    Abstract available

  229. KABA M, Pirincci N, Demir M, Kaba S, et al
    The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
    Int Urol Nephrol. 2023 Jun 20. doi: 10.1007/s11255-023-03666.
    PubMed    
    Abstract available

  230. SARFATY M, Golkaram M, Funt SA, Al-Ahmadie H, et al
    Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
    J Clin Oncol. 2023;41:3225-3235.
    PubMed    
    Abstract available


  231. PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2023;210:222.
    PubMed    


  232. JIA Y, Ding X, Zhou L, Zhang L, et al
    Retraction Note: Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1.
    Oncogene. 2023 May 30. doi: 10.1038/s41388-023-02726.
    PubMed    


  233. BOLENZ C, Kunath F, Zengerling F, Wezel F, et al
    Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials.
    Urol Int. 2023;107:480-488.
    PubMed    
    Abstract available

  234. DU J, Zhan H, Chen J, Wang J, et al
    The Influence of Preoperative Hydronephrosis on the Prognosis after Radical Cystectomy among Patients with Different Pathological Stages of Bladder Cancer.
    Urol Int. 2023 Jun 2:1-8. doi: 10.1159/000531080.
    PubMed    
    Abstract available

  235. GRUNE B, Kowalewski KF, Weiss C, Neuberger M, et al
    Predicting Complexity in Transurethral Resection of Bladder Tumours: External Validation and Modification of the Bladder Complexity Score.
    Urol Int. 2023;107:583-590.
    PubMed    
    Abstract available

  236. GROOTEMAAT M, Tjiam I, Sampimon D, Bot F, et al
    Bilateral Adrenal and testicular Tumours; When a Simple Diagnosis Becomes Complicated.
    Urology. 2023;175:e11-e12.
    PubMed    
    Abstract available

  237. KOLL FJ, Doring C, Olah C, Szarvas T, et al
    Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
    BMC Cancer. 2023;23:504.
    PubMed    
    Abstract available

  238. RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
    BMC Cancer. 2023;23:539.
    PubMed    
    Abstract available

  239. NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
    Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
    BMC Cancer. 2023;23:565.
    PubMed    
    Abstract available

  240. VAINER G, Huang L, Emancipator K, Nuti S, et al
    Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    PLoS One. 2023;18:e0285764.
    PubMed    
    Abstract available

  241. SATO N, Mori KP, Sakai K, Miyata H, et al
    Exploring the mechanism of BK polyomavirus-associated nephropathy through consensus gene network approach.
    PLoS One. 2023;18:e0282534.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;